Last reviewed · How we verify
Pembrolizumab at 35 days post — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Pembrolizumab at 35 days post (Pembrolizumab at 35 days post) — Case Comprehensive Cancer Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pembrolizumab at 35 days post TARGET | Pembrolizumab at 35 days post | Case Comprehensive Cancer Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pembrolizumab at 35 days post CI watch — RSS
- Pembrolizumab at 35 days post CI watch — Atom
- Pembrolizumab at 35 days post CI watch — JSON
- Pembrolizumab at 35 days post alone — RSS
Cite this brief
Drug Landscape (2026). Pembrolizumab at 35 days post — Competitive Intelligence Brief. https://druglandscape.com/ci/pembrolizumab-at-35-days-post. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab